Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1974 Jun;26(6):1145-57.

Studies on the inhibition of C56 initiated lysis (reactive lysis). I. Description of the phenomenon and methods of assay

Studies on the inhibition of C56 initiated lysis (reactive lysis). I. Description of the phenomenon and methods of assay

B McLeod et al. Immunology. 1974 Jun.

Abstract

Reactive lysis refers to the lysis of unsensitized cells by late acting complement components (C5—C9) acting independently of early components. The existence in human serum of an activity which inhibits reactive lysis had been inferred previously from certain morphological features of the reactive lysis of red cells suspended in agarose gels, and from the difficulty with which reactive lysis proceeds in whole serum. We have found this activity, which we abbreviate `INH-RL', in all human sera tested, and in the serum of several experimental animals. We have developed two methods of detection of INH-RL in gels, and have established a sensitive, quantitative assay for INH-RL in solution, which has been adapted to the measurement of INH-RL in serum. We have examined the effect of INH-RL on the measurement of C[unk]56 and C7 by reactive lysis in gels. Inhibition of distal complement components in primary lysis of EAC[unk]142 by INH-RL was detectable but was markedly less potent than inhibition of reactive lysis. INH-RL is distinct from other known complement inhibitors, and thus represents a newly appreciated regulatory mechanism in the complement cascade. It may have importance in quenching the indiscriminate haemolytic activity which can be generated from complement in the fluid phase, especially by stimulation of the alternative pathway.

PubMed Disclaimer

References

    1. J Immunol. 1967 Aug;99(2):263-8 - PubMed
    1. J Immunol. 1967 Sep;99(3):582-9 - PubMed
    1. Immunology. 1967 Oct;13(4):411-20 - PubMed
    1. J Immunol. 1968 Apr;100(4):691-8 - PubMed
    1. Immunology. 1968 May;14(5):745-62 - PubMed

LinkOut - more resources